ARMO BioSciences’ Immunotherapy AM0010 Receives Orphan Drug and Fast Track Designations from the U.S. FDA for the Treatment of Pancreatic Cancer

posted in: News | 0

ARMO BioSciences, Inc., a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted the Company’s lead investigational immuno-oncology drug AM0010 (PEGylated Interleukin-10) Orphan Drug designation for the treatment of pancreatic cancer. The Agency also granted … Continued

Emulate Adds New Capabilities to Human Lung-Chip System for Evaluating Safety of Inhaled Products, Airborne Pollutants, and Patient-Specific Responses to Drugs

posted in: News | 0

Emulate Inc. announced today that its human Lung-Chip system has expanded functionality to now also model conditions in which inhaled toxins enter the lung, including cigarette smoke, e-cigarettes constituents, and potentially environmental airborne contaminants.  The new applications are based on … Continued

Selecta Biosciences Initiates Phase 2 Clinical Trial of SEL-212, First Non-Immunogenic Biologic in Development for Treatment of Gout

posted in: News | 0

Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific immune therapies, today announced that it has dosed the first patient in its Phase 2 clinical trial of SEL-212, the company’s lead proprietary immunotherapeutic product … Continued